Skip to content
2000
image of Pediatric Diffuse High-Grade Gliomas: A Comprehensive Review Of Advanced Methods Of Diagnosis And Treatment

Abstract

Glioblastoma multiforme (GBM) is a complex and aggressive brain tumor that presents significant diagnostic and therapeutic challenges in both adults and children. Understanding the pathogenesis, molecular biology, symptom presentation, and imaging features of GBM is vital for effective therapy. This review summarizes current knowledge on pediatric GBM, specifically Pediatric Diffuse High-Grade Gliomas (pHGG), focusing on diagnosis and treatment. GBM typically arises from the cerebral hemispheres, with gross features marked by heterogeneous morphology and aggressive cell populations. Recent advances in genomic research have shed light on distinct molecular pathways associated with primary and secondary GBMs. Clinical symptoms vary widely but commonly include neurological deficits and increased intracranial pressure. Magnetic resonance imaging (MRI), with its excellent soft tissue contrast, is crucial for diagnosing and monitoring GBM. Emerging techniques, such as diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI), provide insights into the tumor's microstructure and vascularity, assisting in the development of therapeutic strategies and response assessment. Despite advances in imaging, challenges remain in accurately diagnosing and managing pediatric GBM due to its molecular heterogeneity and unique biological behavior. New therapeutic approaches, including targeted therapies and immunotherapy, offer hope for improving outcomes in children with GBM. Clinical trials are ongoing to evaluate these treatments alongside standard options, such as surgery, radiotherapy, and chemotherapy, to meet the unmet needs of pediatric oncology. A multidisciplinary approach, tailored to the individual characteristics of both the patient and the tumor, is essential to optimize treatment and outcomes for pediatric GBM patients. This review highlights the role of advanced MRI techniques in diagnosis, treatment, and monitoring while emphasizing the need for further research and clinical trials to develop more effective therapies for this devastating disease. Recent studies indicate a median survival rate of 12-18 months for pediatric GBM, with treatment response varying based on molecular subtypes. Clinical trials show that IDH-wild-type tumors exhibit poorer prognosis, whereas targeted therapies are improving outcomes in select patient groups.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096365252250618115641
2025-06-30
2025-09-13

  • From This Site

    /content/journals/ccdt/10.2174/0115680096365252250618115641
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ostrom Q.T. Gittleman H. Truitt G. Boscia A. Kruchko C. Barnholtz-Sloan J.S. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-oncol, 2018 20 iv1-iv86 (Suppl. 4) 10.1093/neuonc/noy131 30445539
    [Google Scholar]
  2. Hanif F. Muzaffar K. Perveen K. Malhi S.M. Simjee ShU. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. APJCP 2017 18 1 3 9 10.22034/APJCP.2017.18.1.3 28239999
    [Google Scholar]
  3. Jones C. Perryman L. Hargrave D. Paediatric and adult malignant glioma: Close relatives or distant cousins? Nat. Rev. Clin. Oncol. 2012 9 7 400 413 10.1038/nrclinonc.2012.87 22641364
    [Google Scholar]
  4. Beauchesne P. Extra-neural metastases of malignant gliomas: Myth or reality? Cancers 2011 3 1 461 477 10.3390/cancers3010461 24212625
    [Google Scholar]
  5. Bernstein J.J. Woodard C.A. Glioblastoma cells do not intravasate into blood vessels. Neurosurgery 1995 36 1 124 132 10.1227/00006123‑199501000‑00016 7708148
    [Google Scholar]
  6. Cuddapah V.A. Robel S. Watkins S. Sontheimer H. A neurocentric perspective on glioma invasion. Nat. Rev. Neurosci. 2014 15 7 455 465 10.1038/nrn3765 24946761
    [Google Scholar]
  7. Bellail A.C. Hunter S.B. Brat D.J. Tan C. Van Meir E.G. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. Cell Biol. 2004 36 6 1046 1069 10.1016/j.biocel.2004.01.013 15094120
    [Google Scholar]
  8. Vehlow A. Cordes N. Invasion as target for therapy of glioblastoma multiforme. Biochim. Biophys. Acta Rev. Cancer 2013 1836 2 236 244 10.1016/j.bbcan.2013.07.001 23891970
    [Google Scholar]
  9. Watkins S. Sontheimer H. Hydrodynamic cellular volume changes enable glioma cell invasion. J. Neurosci. 2011 31 47 17250 17259 10.1523/JNEUROSCI.3938‑11.2011 22114291
    [Google Scholar]
  10. Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J. Neurochem. 2008 105 2 287 295 10.1111/j.1471‑4159.2008.05301.x 18284616
    [Google Scholar]
  11. Cuddapah V.A. Sontheimer H. Molecular interaction and functional regulation of ClC-3 by Ca2+/calmodulin-dependent protein kinase II (CaMKII) in human malignant glioma. J. Biol. Chem. 2010 285 15 11188 11196 10.1074/jbc.M109.097675 20139089
    [Google Scholar]
  12. Louis D.N. Perry A. Reifenberger G. von Deimling A. Figarella-Branger D. Cavenee W.K. Ohgaki H. Wiestler O.D. Kleihues P. Ellison D.W. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016 131 6 803 820 10.1007/s00401‑016‑1545‑1 27157931
    [Google Scholar]
  13. Wen P.Y. Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008 359 5 492 507 10.1056/NEJMra0708126 18669428
    [Google Scholar]
  14. Malmer B. Henriksson R. Grönberg H. Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first‐degree relatives of brain tumour patients. Int. J. Cancer 2003 106 2 260 263 10.1002/ijc.11213 12800203
    [Google Scholar]
  15. Goldgar D.E. Easton D.F. Cannon-Albright L.A. Skolnick M.H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J. Natl. Cancer Inst. 1994 86 21 1600 1608 10.1093/jnci/86.21.1600 7932824
    [Google Scholar]
  16. Padmalatha C. Harruff R.C. Ganick D. Hafez G.B. Glioblastoma multiforme with tuberous sclerosis. Report of a case. Arch. Pathol. Lab. Med. 1980 104 12 649 650 [PMID: 6254467
    [Google Scholar]
  17. Hamilton S.R. Liu B. Parsons R.E. Papadopoulos N. Jen J. Powell S.M. Krush A.J. Berk T. Cohen Z. Tetu B. Burger P.C. Wood P.A. Taqi F. Booker S.V. Petersen G.M. Offerhaus G.J.A. Tersmette A.C. Giardiello F.M. Vogelstein B. Kinzler K.W. The molecular basis of Turcot’s syndrome. N. Engl. J. Med. 1995 332 13 839 847 10.1056/NEJM199503303321302 7661930
    [Google Scholar]
  18. Gianno F. Giovannoni I. Cafferata B. Diomedi-Camassei F. Minasi S. Barresi S. Buttarelli F.R. Alesi V. Cardoni A. Antonelli M. Puggioni C. Colafati G.S. Carai A. Vinci M. Mastronuzzi A. Miele E. Alaggio R. Giangaspero F. Rossi S. Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO classification. Pathologica 2022 114 6 422 435 10.32074/1591‑951X‑830 36534421
    [Google Scholar]
  19. Gutmann D.H. James C.D. Poyhonen M. Louis D.N. Ferner R. Guha A. Hariharan S. Viskochil D. Perry A. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 2003 61 10 1397 1400 10.1212/WNL.61.10.1397 14638962
    [Google Scholar]
  20. Furnari F.B. Fenton T. Bachoo R.M. Mukasa A. Stommel J.M. Stegh A. Hahn W.C. Ligon K.L. Louis D.N. Brennan C. Chin L. DePinho R.A. Cavenee W.K. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 2007 21 21 2683 2710 10.1101/gad.1596707 17974913
    [Google Scholar]
  21. Mao H. LeBrun D.G. Yang J. Zhu V.F. Li M. Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets. Cancer Invest. 2012 30 1 48 56 10.3109/07357907.2011.630050 22236189
    [Google Scholar]
  22. Zhu Y. Parada L.F. The molecular and genetic basis of neurological tumours. Nat. Rev. Cancer 2002 2 8 616 626 10.1038/nrc866 12154354
    [Google Scholar]
  23. Kabat G.C. Etgen A.M. Rohan T.E. Do steroid hormones play a role in the etiology of glioma? Cancer Epidemiol. Biomarkers Prev. 2010 19 10 2421 2427 10.1158/1055‑9965.EPI‑10‑0658 20841389
    [Google Scholar]
  24. Cobbs C.S. Cytomegalovirus and brain tumor. Curr. Opin. Oncol. 2013 25 6 682 688 10.1097/CCO.0000000000000005 24097102
    [Google Scholar]
  25. Dziurzynski K. Chang S.M. Heimberger A.B. Kalejta R.F. McGregor Dallas S.R. Smit M. Soroceanu L. Cobbs C.S. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro-oncol. 2012 14 3 246 255 10.1093/neuonc/nor227 22319219
    [Google Scholar]
  26. Soroceanu L. Matlaf L. Bezrookove V. Harkins L. Martinez R. Greene M. Soteropoulos P. Cobbs C.S. Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res. 2011 71 21 6643 6653 10.1158/0008‑5472.CAN‑11‑0744 21900396
    [Google Scholar]
  27. Ostrom Q.T. Bauchet L. Davis F.G. Deltour I. Fisher J.L. Langer C.E. Pekmezci M. Schwartzbaum J.A. Turner M.C. Walsh K.M. Wrensch M.R. Barnholtz-Sloan J.S. The epidemiology of glioma in adults: A “state of the science” review. Neuro-oncol. 2014 16 7 896 913 10.1093/neuonc/nou087 24842956
    [Google Scholar]
  28. Brain tumour risk in relation to mobile telephone use: Results of the INTERPHONE international case–control study. Int. J. Epidemiol. 2010 39 3 675 694 10.1093/ije/dyq079 20483835
    [Google Scholar]
  29. Alexander B.M. Cloughesy T.F. Adult Glioblastoma. J. Clin. Oncol. 2017 35 21 2402 2409 10.1200/JCO.2017.73.0119 28640706
    [Google Scholar]
  30. Gorlia T. van den Bent M.J. Hegi M.E. Mirimanoff R.O. Weller M. Cairncross J.G. Eisenhauer E. Belanger K. Brandes A.A. Allgeier A. Lacombe D. Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008 9 1 29 38 10.1016/S1470‑2045(07)70384‑4 18082451
    [Google Scholar]
  31. Mirimanoff R.O. Gorlia T. Mason W. Van den Bent M.J. Kortmann R.D. Fisher B. Reni M. Brandes A.A. Curschmann J. Villa S. Cairncross G. Allgeier A. Lacombe D. Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J. Clin. Oncol. 2006 24 16 2563 2569 10.1200/JCO.2005.04.5963 16735709
    [Google Scholar]
  32. Lamborn K.R. Chang S.M. Prados M.D. Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro-oncol. 2004 6 3 227 235 10.1215/S1152851703000620 15279715
    [Google Scholar]
  33. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008 455 7216 1061 1068 10.1038/nature07385 18772890
    [Google Scholar]
  34. Verhaak R.G.W. Hoadley K.A. Purdom E. Wang V. Qi Y. Wilkerson M.D. Miller C.R. Ding L. Golub T. Mesirov J.P. Alexe G. Lawrence M. O’Kelly M. Tamayo P. Weir B.A. Gabriel S. Winckler W. Gupta S. Jakkula L. Feiler H.S. Hodgson J.G. James C.D. Sarkaria J.N. Brennan C. Kahn A. Spellman P.T. Wilson R.K. Speed T.P. Gray J.W. Meyerson M. Getz G. Perou C.M. Hayes D.N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010 17 1 98 110 10.1016/j.ccr.2009.12.020 20129251
    [Google Scholar]
  35. Engelman J.A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 2009 9 8 550 562 10.1038/nrc2664 19629070
    [Google Scholar]
  36. Song M.S. Salmena L. Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012 13 5 283 296 10.1038/nrm3330 22473468
    [Google Scholar]
  37. Kiessling M. Rogler G. Targeting the RAS pathway by mitogen-activated protein kinase inhibitors. Swiss Med. Wkly. 2015 145 5152 w14207 10.4414/smw.2015.14207 26691679
    [Google Scholar]
  38. Gan H.K. Cvrljevic A.N. Johns T.G. The epidermal growth factor receptor variant III (EGFR v III): Where wild things are altered. FEBS J. 2013 280 21 5350 5370 10.1111/febs.12393 23777544
    [Google Scholar]
  39. Massacesi C. Di Tomaso E. Urban P. Germa C. Quadt C. Trandafir L. Aimone P. Fretault N. Dharan B. Tavorath R. Hirawat S. PI3K inhibitors as new cancer therapeutics: Implications for clinical trial design. OncoTargets Ther. 2016 9 203 210 10.2147/OTT.S89967 26793003
    [Google Scholar]
  40. Torp S.H. Solheim O. Skjulsvik A.J. The WHO 2021 classification of central nervous system tumours: A practical update on what neurosurgeons need to know—a minireview. Acta Neurochir. (Wien) 2022 164 9 2453 2464 10.1007/s00701‑022‑05301‑y 35879477
    [Google Scholar]
  41. Ohgaki H. Kleihues P. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 2013 19 4 764 772 10.1158/1078‑0432.CCR‑12‑3002 23209033
    [Google Scholar]
  42. Buccoliero A.M. Giunti L. Moscardi S. Castiglione F. Provenzano A. Sardi I. Scagnet M. Genitori L. Caporalini C. Pediatric high grade glioma classification criteria and molecular features of a case series. Genes 2022 13 4 624 10.3390/genes13040624 35456430
    [Google Scholar]
  43. Cohen K.J. Pollack I.F. Zhou T. Buxton A. Holmes E.J. Burger P.C. Brat D.J. Rosenblum M.K. Hamilton R.L. Lavey R.S. Heideman R.L. Temozolomide in the treatment of high-grade gliomas in children: A report from the Children’s Oncology Group. Neuro-oncol. 2011 13 3 317 323 10.1093/neuonc/noq191 21339192
    [Google Scholar]
  44. Fangusaro J. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J. Child Neurol. 2009 24 11 1409 1417 10.1177/0883073809338960 19638636
    [Google Scholar]
  45. Jones C. Baker S.J. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat. Rev. Cancer 2014 14 10 651 661 10.1038/nrc3811 25230881
    [Google Scholar]
  46. Sturm D. Pfister S.M. Jones D.T.W. Pediatric gliomas: Current concepts on diagnosis, biology, and clinical management. J. Clin. Oncol. 2017 35 21 2370 2377 10.1200/JCO.2017.73.0242 28640698
    [Google Scholar]
  47. Warren K.E. Diffuse intrinsic pontine glioma: Poised for progress. Front. Oncol. 2012 2 205 10.3389/fonc.2012.00205 23293772
    [Google Scholar]
  48. Pollack I.F. Agnihotri S. Broniscer A. Childhood brain tumors: Current management, biological insights, and future directions. J. Neurosurg. Pediatr. 2019 23 3 261 273 10.3171/2018.10.PEDS18377 30835699
    [Google Scholar]
  49. Yang K. Wu Z. Zhang H. Zhang N. Wu W. Wang Z. Dai Z. Zhang X. Zhang L. Peng Y. Ye W. Zeng W. Liu Z. Cheng Q. Glioma targeted therapy: Insight into future of molecular approaches. Mol. Cancer 2022 21 1 39 10.1186/s12943‑022‑01513‑z 35135556
    [Google Scholar]
  50. MacDonald T.J. Aguilera D. Kramm C.M. Treatment of high-grade glioma in children and adolescents. Neuro-oncol. 2011 13 10 1049 1058 10.1093/neuonc/nor092 21784756
    [Google Scholar]
  51. Hargrave D. Bartels U. Bouffet E. Diffuse brainstem glioma in children: Critical review of clinical trials. Lancet Oncol. 2006 7 3 241 248 10.1016/S1470‑2045(06)70615‑5 16510333
    [Google Scholar]
  52. Fangusaro J. Pediatric high grade glioma: A review and update on tumor clinical characteristics and biology. Front. Oncol. 2012 2 105 10.3389/fonc.2012.00105 22937526
    [Google Scholar]
  53. Jones C. Karajannis M.A. Jones D.T.W. Kieran M.W. Monje M. Baker S.J. Becher O.J. Cho Y.J. Gupta N. Hawkins C. Hargrave D. Haas-Kogan D.A. Jabado N. Li X.N. Mueller S. Nicolaides T. Packer R.J. Persson A.I. Phillips J.J. Simonds E.F. Stafford J.M. Tang Y. Pfister S.M. Weiss W.A. Pediatric high-grade glioma: Biologically and clinically in need of new thinking. Neuro-oncol. 2016 19 2 now101 10.1093/neuonc/now101 27282398
    [Google Scholar]
  54. Pollack I.F. Hamilton R.L. Sobol R.W. Nikiforova M.N. Lyons-Weiler M.A. LaFramboise W.A. Burger P.C. Brat D.J. Rosenblum M.K. Holmes E.J. Zhou T. Jakacki R.I. IDH1 mutations are common in malignant gliomas arising in adolescents: A report from the Children’s Oncology Group. Childs Nerv. Syst. 2011 27 1 87 94 10.1007/s00381‑010‑1264‑1 20725730
    [Google Scholar]
  55. Schwartzentruber J. Korshunov A. Liu X.Y. Jones D.T.W. Pfaff E. Jacob K. Sturm D. Fontebasso A.M. Quang D.A.K. Tönjes M. Hovestadt V. Albrecht S. Kool M. Nantel A. Konermann C. Lindroth A. Jäger N. Rausch T. Ryzhova M. Korbel J.O. Hielscher T. Hauser P. Garami M. Klekner A. Bognar L. Ebinger M. Schuhmann M.U. Scheurlen W. Pekrun A. Frühwald M.C. Roggendorf W. Kramm C. Dürken M. Atkinson J. Lepage P. Montpetit A. Zakrzewska M. Zakrzewski K. Liberski P.P. Dong Z. Siegel P. Kulozik A.E. Zapatka M. Guha A. Malkin D. Felsberg J. Reifenberger G. von Deimling A. Ichimura K. Collins V.P. Witt H. Milde T. Witt O. Zhang C. Castelo-Branco P. Lichter P. Faury D. Tabori U. Plass C. Majewski J. Pfister S.M. Jabado N. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012 482 7384 226 231 10.1038/nature10833 22286061
    [Google Scholar]
  56. Bae W.H. Maraka S. Daher A. Challenges and advances in glioblastoma targeted therapy: The promise of drug repurposing and biomarker exploration. Front. Oncol. 2024 14 1441460 10.3389/fonc.2024.1441460 39439947
    [Google Scholar]
  57. Ramaswamy V. Remke M. Bouffet E. Bailey S. Clifford S.C. Doz F. Kool M. Dufour C. Vassal G. Milde T. Witt O. von Hoff K. Pietsch T. Northcott P.A. Gajjar A. Robinson G.W. Padovani L. André N. Massimino M. Pizer B. Packer R. Rutkowski S. Pfister S.M. Taylor M.D. Pomeroy S.L. Risk stratification of childhood medulloblastoma in the molecular era: The current consensus. Acta Neuropathol. 2016 131 6 821 831 10.1007/s00401‑016‑1569‑6 27040285
    [Google Scholar]
  58. Stupp R. Mason W.P. van den Bent M.J. Weller M. Fisher B. Taphoorn M.J.B. Belanger K. Brandes A.A. Marosi C. Bogdahn U. Curschmann J. Janzer R.C. Ludwin S.K. Gorlia T. Allgeier A. Lacombe D. Cairncross J.G. Eisenhauer E. Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005 352 10 987 996 10.1056/NEJMoa043330 15758009
    [Google Scholar]
  59. Lacroix M. Abi-Said D. Fourney D.R. Gokaslan Z.L. Shi W. DeMonte F. Lang F.F. McCutcheon I.E. Hassenbusch S.J. Holland E. Hess K. Michael C. Miller D. Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J. Neurosurg. 2001 95 2 190 198 10.3171/jns.2001.95.2.0190 11780887
    [Google Scholar]
  60. Stupp R. Hegi M.E. Mason W.P. van den Bent M.J. Taphoorn M.J.B. Janzer R.C. Ludwin S.K. Allgeier A. Fisher B. Belanger K. Hau P. Brandes A.A. Gijtenbeek J. Marosi C. Vecht C.J. Mokhtari K. Wesseling P. Villa S. Eisenhauer E. Gorlia T. Weller M. Lacombe D. Cairncross J.G. Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 10 5 459 466 10.1016/S1470‑2045(09)70025‑7 19269895
    [Google Scholar]
  61. Hegi M.E. Diserens A.C. Gorlia T. Hamou M.F. de Tribolet N. Weller M. Kros J.M. Hainfellner J.A. Mason W. Mariani L. Bromberg J.E.C. Hau P. Mirimanoff R.O. Cairncross J.G. Janzer R.C. Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005 352 10 997 1003 10.1056/NEJMoa043331 15758010
    [Google Scholar]
  62. Merchant T.E. Pollack I.F. Loeffler J.S. Brain tumors across the age spectrum: Biology, therapy, and late effects. Semin. Radiat. Oncol. 2010 20 1 58 66 10.1016/j.semradonc.2009.09.005 19959032
    [Google Scholar]
  63. Ostrom Q.T. de Blank P.M. Kruchko C. Petersen C.M. Liao P. Finlay J.L. Stearns D.S. Wolff J.E. Wolinsky Y. Letterio J.J. Barnholtz-Sloan J.S. Alex’s lemonade stand foundation infant and childhood primary brain and central nervous system tumors diag-nosed in the United States in 2007–2011 Neuro-oncol, 2015 6 16(Suppl 10), x1-x36.(Suppl. 10) 10.1093/neuonc/nou327 25542864
    [Google Scholar]
  64. Pollack I.F. Boyett J.M. Yates A.J. Burger P.C. Gilles F.H. Davis R.L. Finlay J.L. The influence of central review on outcome associations in childhood malignant gliomas: Results from the CCG-945 experience. Neuro-oncol. 2003 5 3 197 207 10.1215/S1152851703000097 12816726
    [Google Scholar]
  65. Das K.K. Kumar R. Pediatric Glioblastoma. Glioblastoma. Codon Publications 2017 10.15586/codon.glioblastoma.2017.ch15
    [Google Scholar]
  66. Sturm D. Witt H. Hovestadt V. Khuong-Quang D.A. Jones D.T.W. Konermann C. Pfaff E. Tönjes M. Sill M. Bender S. Kool M. Zapatka M. Becker N. Zucknick M. Hielscher T. Liu X.Y. Fontebasso A.M. Ryzhova M. Albrecht S. Jacob K. Wolter M. Ebinger M. Schuhmann M.U. van Meter T. Frühwald M.C. Hauch H. Pekrun A. Radlwimmer B. Niehues T. von Komorowski G. Dürken M. Kulozik A.E. Madden J. Donson A. Foreman N.K. Drissi R. Fouladi M. Scheurlen W. von Deimling A. Monoranu C. Roggendorf W. Herold-Mende C. Unterberg A. Kramm C.M. Felsberg J. Hartmann C. Wiestler B. Wick W. Milde T. Witt O. Lindroth A.M. Schwartzentruber J. Faury D. Fleming A. Zakrzewska M. Liberski P.P. Zakrzewski K. Hauser P. Garami M. Klekner A. Bognar L. Morrissy S. Cavalli F. Taylor M.D. van Sluis P. Koster J. Versteeg R. Volckmann R. Mikkelsen T. Aldape K. Reifenberger G. Collins V.P. Majewski J. Korshunov A. Lichter P. Plass C. Jabado N. Pfister S.M. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012 22 4 425 437 10.1016/j.ccr.2012.08.024 23079654
    [Google Scholar]
  67. Faury D. Nantel A. Dunn S.E. Guiot M.C. Haque T. Hauser P. Garami M. Bognár L. Hanzély Z. Liberski P.P. Lopez-Aguilar E. Valera E.T. Tone L.G. Carret A.S. Del Maestro R.F. Gleave M. Montes J.L. Pietsch T. Albrecht S. Jabado N. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J. Clin. Oncol. 2007 25 10 1196 1208 10.1200/JCO.2006.07.8626 17401009
    [Google Scholar]
  68. Broniscer A. Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: Two challenges for the pediatric oncologist. Oncologist 2004 9 2 197 206 10.1634/theoncologist.9‑2‑197 15047924
    [Google Scholar]
  69. Quail D.F. Joyce J.A. The microenvironmental landscape of brain tumors. Cancer Cell 2017 31 3 326 341 10.1016/j.ccell.2017.02.009 28292436
    [Google Scholar]
  70. Chen X. Cui Y. Zou L. Treatment advances in high-grade gliomas. Front. Oncol. 2024 14 1287725 10.3389/fonc.2024.1287725 38660136
    [Google Scholar]
  71. Mackay A. Burford A. Carvalho D. Izquierdo E. Fazal-Salom J. Taylor K.R. Bjerke L. Clarke M. Vinci M. Nandhabalan M. Temelso S. Popov S. Molinari V. Raman P. Waanders A.J. Han H.J. Gupta S. Marshall L. Zacharoulis S. Vaidya S. Mandeville H.C. Bridges L.R. Martin A.J. Al-Sarraj S. Chandler C. Ng H.K. Li X. Mu K. Trabelsi S. Brahim D.H.B. Kisljakov A.N. Konovalov D.M. Moore A.S. Carcaboso A.M. Sunol M. de Torres C. Cruz O. Mora J. Shats L.I. Stavale J.N. Bidinotto L.T. Reis R.M. Entz-Werle N. Farrell M. Cryan J. Crimmins D. Caird J. Pears J. Monje M. Debily M.A. Castel D. Grill J. Hawkins C. Nikbakht H. Jabado N. Baker S.J. Pfister S.M. Jones D.T.W. Fouladi M. von Bueren A.O. Baudis M. Resnick A. Jones C. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017 32 4 520 537.e5 10.1016/j.ccell.2017.08.017 28966033
    [Google Scholar]
  72. Weller M. Wen P.Y. Chang S.M. Dirven L. Lim M. Monje M. Reifenberger G. Glioma. Nat. Rev. Dis. Primers 2024 10 1 33 10.1038/s41572‑024‑00516‑y 38724526
    [Google Scholar]
  73. Stummer W. Pichlmeier U. Meinel T. Wiestler O.D. Zanella F. Reulen H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol. 2006 7 5 392 401 10.1016/S1470‑2045(06)70665‑9 16648043
    [Google Scholar]
  74. Ellingson B.M. Bendszus M. Boxerman J. Barboriak D. Erickson B.J. Smits M. Nelson S.J. Gerstner E. Alexander B. Goldmacher G. Wick W. Vogelbaum M. Weller M. Galanis E. Kalpathy-Cramer J. Shankar L. Jacobs P. Pope W.B. Yang D. Chung C. Knopp M.V. Cha S. van den Bent M.J. Chang S. Yung W.K. Cloughesy T.F. Wen P.Y. Gilbert M.R. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro-oncol. 2015 17 9 1188 1198 10.1093/neuonc/nov095 26250565
    [Google Scholar]
  75. Chawla S. Wang S. Wolf R.L. Woo J.H. Wang J. O’Rourke D.M. Judy K.D. Grady M.S. Melhem E.R. Poptani H. Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am. J. Neuroradiol. 2007 28 9 1683 1689 10.3174/ajnr.A0673 17893221
    [Google Scholar]
  76. Troudi A. Tensaouti F. Baudou E. Péran P. Laprie A. Arterial spin labeling perfusion in pediatric brain tumors: A review of techniques, quality control, and quantification. Cancers 2022 14 19 4734 10.3390/cancers14194734 36230655
    [Google Scholar]
  77. Martucci M. Russo R. Giordano C. Schiarelli C. D’Apolito G. Tuzza L. Lisi F. Ferrara G. Schimperna F. Vassalli S. Calandrelli R. Gaudino S. Advanced magnetic resonance imaging in the evaluation of treated glioblastoma: A pictorial essay. Cancers 2023 15 15 3790 10.3390/cancers15153790 37568606
    [Google Scholar]
  78. Choi C. Ganji S.K. DeBerardinis R.J. Hatanpaa K.J. Rakheja D. Kovacs Z. Yang X.L. Mashimo T. Raisanen J.M. Marin-Valencia I. Pascual J.M. Madden C.J. Mickey B.E. Malloy C.R. Bachoo R.M. Maher E.A. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 2012 18 4 624 629 10.1038/nm.2682 22281806
    [Google Scholar]
  79. Cloughesy T.F. Mochizuki A.Y. Orpilla J.R. Hugo W. Lee A.H. Davidson T.B. Wang A.C. Ellingson B.M. Rytlewski J.A. Sanders C.M. Kawaguchi E.S. Du L. Li G. Yong W.H. Gaffey S.C. Cohen A.L. Mellinghoff I.K. Lee E.Q. Reardon D.A. O’Brien B.J. Butowski N.A. Nghiemphu P.L. Clarke J.L. Arrillaga-Romany I.C. Colman H. Kaley T.J. de Groot J.F. Liau L.M. Wen P.Y. Prins R.M. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 2019 25 3 477 486 10.1038/s41591‑018‑0337‑7 30742122
    [Google Scholar]
  80. Gardner S.L. Tarapore R.S. Allen J. McGovern S.L. Zaky W. Odia Y. Daghistani D. Diaz Z. Hall M.D. Khatib Z. Koschmann C. Cantor E. Kurokawa R. MacDonald T.J. Aguilera D. Vitanza N.A. Mueller S. Kline C. Lu G. Allen J.E. Khatua S. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neurooncol. Adv. 2022 4 1 vdac143 10.1093/noajnl/vdac143 36382108
    [Google Scholar]
  81. Sampson J.H. Gunn M.D. Fecci P.E. Ashley D.M. Brain immunology and immunotherapy in brain tumours. Nat. Rev. Cancer 2020 20 1 12 25 10.1038/s41568‑019‑0224‑7 31806885
    [Google Scholar]
  82. O’Rourke D.M. Nasrallah M.P. Desai A. Melenhorst J.J. Mansfield K. Morrissette J.J.D. Martinez-Lage M. Brem S. Maloney E. Shen A. Isaacs R. Mohan S. Plesa G. Lacey S.F. Navenot J.M. Zheng Z. Levine B.L. Okada H. June C.H. Brogdon J.L. Maus M.V. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 2017 9 399 eaaa0984 10.1126/scitranslmed.aaa0984 28724573
    [Google Scholar]
  83. Wick W. Gorlia T. Bendszus M. Taphoorn M. Sahm F. Harting I. Brandes A.A. Taal W. Domont J. Idbaih A. Campone M. Clement P.M. Stupp R. Fabbro M. Le Rhun E. Dubois F. Weller M. von Deimling A. Golfinopoulos V. Bromberg J.C. Platten M. Klein M. van den Bent M.J. Lomustine and bevacizumab in progressive glioblastoma. N. Engl. J. Med. 2017 377 20 1954 1963 10.1056/NEJMoa1707358 29141164
    [Google Scholar]
  84. Gan H.K. Papadopoulos K.P. Fichtel L. Lassman A.B. Merrell R. Van Den Bent M.J. Kumthekar P. Scott A.M. Pedersen M. Gomez E.J. Fischer J.S. Phase I study of ABT-414 mono-or com-bination therapy with temozolomide (TMZ) in recurrent glioblas-toma (GBM). Meeting abstract: 2015 ASCO annual meeting I. J. Clin. Oncol 2015 33 2016 (Suppl. 15) 10.1200/jco.2015.33.15_suppl.2016
    [Google Scholar]
  85. Hervás-Corpión I. Alonso M.M. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success. Int. Rev. Cell Mol. Biol. 2023 379 169 188 10.1016/bs.ircmb.2023.04.001 37541723
    [Google Scholar]
  86. Cruz Da Silva E. Mercier M.C. Etienne-Selloum N. Dontenwill M. Choulier L. A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers 2021 13 8 1795 10.3390/cancers13081795 33918704
    [Google Scholar]
  87. Le Rhun E. Preusser M. Roth P. Reardon D.A. van den Bent M. Wen P. Reifenberger G. Weller M. Molecular targeted therapy of glioblastoma. Cancer Treat. Rev. 2019 80 101896 10.1016/j.ctrv.2019.101896 31541850
    [Google Scholar]
  88. Arrillaga-Romany I. Chi A.S. Allen J.E. Oster W. Wen P.Y. Batchelor T.T. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 2017 8 45 79298 79304 10.18632/oncotarget.17837 29108308
    [Google Scholar]
  89. Kline C.L.B. Van den Heuvel A.P.J. Allen J.E. Prabhu V.V. Dicker D.T. El-Deiry W.S. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Sci. Signal. 2016 9 415 ra18 10.1126/scisignal.aac4374 26884600
    [Google Scholar]
  90. Chi A.S. Tarapore R.S. Hall M.D. Shonka N. Gardner S. Umemura Y. Sumrall A. Khatib Z. Mueller S. Kline C. Zaky W. Khatua S. Weathers S.P. Odia Y. Niazi T.N. Daghistani D. Cherrick I. Korones D. Karajannis M.A. Kong X.T. Minturn J. Waanders A. Arillaga-Romany I. Batchelor T. Wen P.Y. Merdinger K. Schalop L. Stogniew M. Allen J.E. Oster W. Mehta M.P. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J. Neurooncol. 2019 145 1 97 105 10.1007/s11060‑019‑03271‑3 31456142
    [Google Scholar]
  91. Wen P.Y. Cloughesy T.F. Olivero A.G. Morrissey K.M. Wilson T.R. Lu X. Mueller L.U. Coimbra A.F. Ellingson B.M. Gerstner E. Lee E.Q. Rodon J. First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Clin. Cancer Res. 2020 26 8 1820 1828 10.1158/1078‑0432.CCR‑19‑2808 31937616
    [Google Scholar]
  92. Brennan CW Verhaak RG McKenna A Campos B Noushmehr H Salama SR Zheng S Chakravarty D Sanborn JZ Berman SH Beroukhim R The somatic genomic landscape of glioblastoma. Cell 2013 155 2 462 477 10.1016/j.cell.2013.09.034 24120142
    [Google Scholar]
  93. Stupp R. Taillibert S. Kanner A. Read W. Steinberg D.M. Lhermitte B. Toms S. Idbaih A. Ahluwalia M.S. Fink K. Di Meco F. Lieberman F. Zhu J.J. Stragliotto G. Tran D.D. Brem S. Hottinger A.F. Kirson E.D. Lavy-Shahaf G. Weinberg U. Kim C.Y. Paek S.H. Nicholas G. Bruna J. Hirte H. Weller M. Palti Y. Hegi M.E. Ram Z. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 2017 318 23 2306 2316 10.1001/jama.2017.18718 29260225
    [Google Scholar]
  94. Bady P. Sciuscio D. Diserens A.C. Bloch J. van den Bent M.J. Marosi C. Dietrich P.Y. Weller M. Mariani L. Heppner F.L. Mcdonald D.R. Lacombe D. Stupp R. Delorenzi M. Hegi M.E. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012 124 4 547 560 10.1007/s00401‑012‑1016‑2 22810491
    [Google Scholar]
  95. Hygino da Cruz L.C. Rodriguez I. Domingues R.C. Gasparetto E.L. Sorensen A.G. Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma. AJNR Am. J. Neuroradiol. 2011 32 11 1978 1985 10.3174/ajnr.A2397 21393407
    [Google Scholar]
  96. Essig M. Shiroishi M.S. Nguyen T.B. Saake M. Provenzale J.M. Enterline D. Anzalone N. Dörfler A. Rovira À. Wintermark M. Law M. Perfusion MRI: The five most frequently asked technical questions. AJR Am. J. Roentgenol. 2013 200 1 24 34 10.2214/AJR.12.9543 23255738
    [Google Scholar]
  97. Boxerman J.L. Schmainda K.M. Weisskoff R.M. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am. J. Neuroradiol. 2006 27 4 859 867 [PMID: 16611779
    [Google Scholar]
  98. Detre J.A. Rao H. Wang D.J.J. Chen Y.F. Wang Z. Applications of arterial spin labeled MRI in the brain. J. Magn. Reson. Imaging 2012 35 5 1026 1037 10.1002/jmri.23581 22246782
    [Google Scholar]
  99. Pillai J.J. Zacà D. Comparison of BOLD cerebrovascular reactivity mapping and DSC MR perfusion imaging for prediction of neurovascular uncoupling potential in brain tumors. Technol. Cancer Res. Treat. 2012 11 4 361 374 10.7785/tcrt.2012.500284 22376130
    [Google Scholar]
  100. Leather T. Jenkinson M. Das K. Poptani H. Magnetic resonance spectroscopy for detection of 2-hydroxyglutarate as a biomarker for IDH mutation in gliomas. Metabolites 2017 7 2 29 10.3390/metabo7020029 28629182
    [Google Scholar]
  101. Jellison B.J. Field A.S. Medow J. Lazar M. Salamat M.S. Alexander A.L. Diffusion tensor imaging of cerebral white matter: A pictorial review of physics, fiber tract anatomy, and tumor imaging patterns. AJNR Am. J. Neuroradiol. 2004 25 3 356 369 [PMID: 15037456
    [Google Scholar]
  102. Fangusaro J. Bandopadhayay P. The “risk” in pediatric low-grade glioma. Cancer Cell 2020 37 4 424 425 10.1016/j.ccell.2020.03.020 32289265
    [Google Scholar]
  103. de Blank P. Bandopadhayay P. Haas-Kogan D. Fouladi M. Fangusaro J. Management of pediatric low-grade glioma. Curr. Opin. Pediatr. 2019 31 1 21 27 10.1097/MOP.0000000000000717 30531227
    [Google Scholar]
  104. Packer R.J. Gajjar A. Vezina G. Rorke-Adams L. Burger P.C. Robertson P.L. Bayer L. LaFond D. Donahue B.R. Marymont M.H. Muraszko K. Langston J. Sposto R. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 2006 24 25 4202 4208 10.1200/JCO.2006.06.4980 16943538
    [Google Scholar]
  105. Wolff J.E.A. Driever P.H. Erdlenbruch B. Kortmann R.D. Rutkowski S. Pietsch T. Parker C. Metz M.W. Gnekow A. Kramm C.M. Intensive chemotherapy improves survival in pediatric high‐grade glioma after gross total resection: Results of the HIT‐GBM‐C protocol. Cancer 2010 116 3 705 712 10.1002/cncr.24730 19957326
    [Google Scholar]
  106. Staunton J Ziegler DS Temozolomide for paediatric high-grade gli-oma: Time for a rethink?. hem-onc 2023 19 2 4 6 10.17925/OHR.2023.19.2.4
    [Google Scholar]
  107. Khatua S. Sadighi Z.S. Pearlman M.L. Bochare S. Vats T.S. Brain tumors in children--current therapies and newer directions. Indian J. Pediatr. 2012 79 7 922 927 10.1007/s12098‑012‑0689‑9 22294272
    [Google Scholar]
  108. Rončević A. Koruga N. Soldo Koruga A. Rončević R. Rotim T. Šimundić T. Kretić D. Perić M. Turk T. Štimac D. Personalized treatment of glioblastoma: Current state and future perspective. Biomedicines 2023 11 6 1579 10.3390/biomedicines11061579 37371674
    [Google Scholar]
  109. Eder K. Kalman B. Molecular heterogeneity of glioblastoma and its clinical relevance. Pathol. Oncol. Res. 2014 20 4 777 787 10.1007/s12253‑014‑9833‑3 25156108
    [Google Scholar]
  110. Lim M. Xia Y. Bettegowda C. Weller M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 2018 15 7 422 442 10.1038/s41571‑018‑0003‑5 29643471
    [Google Scholar]
  111. Aldape K. Brindle K.M. Chesler L. Chopra R. Gajjar A. Gilbert M.R. Gottardo N. Gutmann D.H. Hargrave D. Holland E.C. Jones D.T.W. Joyce J.A. Kearns P. Kieran M.W. Mellinghoff I.K. Merchant M. Pfister S.M. Pollard S.M. Ramaswamy V. Rich J.N. Robinson G.W. Rowitch D.H. Sampson J.H. Taylor M.D. Workman P. Gilbertson R.J. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 2019 16 8 509 520 10.1038/s41571‑019‑0177‑5 30733593
    [Google Scholar]
  112. Buczkowicz P. Hawkins C. Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma. Front. Oncol. 2015 5 147 10.3389/fonc.2015.00147 26175967
    [Google Scholar]
  113. Sarkaria J.N. Hu L.S. Parney I.F. Pafundi D.H. Brinkmann D.H. Laack N.N. Giannini C. Burns T.C. Kizilbash S.H. Laramy J.K. Swanson K.R. Kaufmann T.J. Brown P.D. Agar N.Y.R. Galanis E. Buckner J.C. Elmquist W.F. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-oncol. 2018 20 2 184 191 10.1093/neuonc/nox175 29016900
    [Google Scholar]
  114. Armstrong G.T. Kawashima T. Leisenring W. Stratton K. Stovall M. Hudson M.M. Sklar C.A. Robison L.L. Oeffinger K.C. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J. Clin. Oncol. 2014 32 12 1218 1227 10.1200/JCO.2013.51.1055 24638000
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096365252250618115641
Loading
Pediatric Diffuse High-Grade Gliomas: A Comprehensive Review Of Advanced Methods Of Diagnosis And Treatment
Bentham Science Publishers ; https://doi.org/10.2174/0115680096365252250618115641
/content/journals/ccdt/10.2174/0115680096365252250618115641
/content/journals/ccdt/10.2174/0115680096365252250618115641
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: MRI ; PET ; Pediatric diffuse high-grade glioma (pHGG) ; ionizing radiation ; imaging technique ; tumor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test